{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T10:04:40Z","timestamp":1762509880890,"version":"build-2065373602"},"reference-count":67,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:p>Drug-resistant epilepsy (DRE) remains a major clinical challenge, with up to one-third of patients experiencing uncontrolled seizures despite polytherapy. Ivermectin (IVM), a macrocyclic lactone with antiparasitic, neuromodulatory, and anti-inflammatory properties, has recently emerged as a candidate adjunctive therapy. We conducted an observational study including 146 patients with highly refractory epilepsy treated with IVM in addition to standard antiseizure medication (ASM). Clinical outcomes were assessed before and after IVM initiation, with seizure frequency recorded from patient diaries and seizure control classified according to International League Against Epilepsy criteria. IVM was administered orally, dissolved in propylene glycol, at doses ranging from 30 to 280\u2005mg\/week. After treatment, mean annual seizure frequency decreased by 88.9%, with consistent benefits across subgroups, including patients with cluster seizures (86.4% reduction). More than 90% of participants achieved seizure freedom, and all patients reported some degree of seizure reduction. Concomitant ASM burden decreased by 22%, reflecting improved tolerability and adherence, and no major safety concerns were observed. Mechanistically, the antiseizure potential of IVM may involve modulation of neuronal excitability, neuroinflammatory pathways, and blood\u2013brain barrier transport dynamics, as supported by experimental evidence. These findings align with epidemiological data on onchocerciasis-associated epilepsy and recent controlled trials of IVM formulations in focal epilepsy. While further randomized studies are needed to confirm optimal dosing, safety monitoring, and mechanistic correlates, our results provide real-world evidence that IVM represents a promising adjunctive option for the management of refractory epilepsy.<\/jats:p>","DOI":"10.1097\/fbp.0000000000000858","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T02:00:23Z","timestamp":1761012023000},"page":"588-595","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Ivermectin: a therapeutic strategy to treat patients with resistant epilepsy"],"prefix":"10.1097","volume":"36","author":[{"given":"Diana Carolina","family":"Ortega","sequence":"first","affiliation":[{"name":"Neurology Outpatient, Neurological Care Center \u2018Neur\u00f3logos de Occidente\u2019, Cali, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Prieto-Valiente","sequence":"additional","affiliation":[{"name":"Universidad Cat\u00f3lica de Murcia UCAM, Murcia, Espa\u00f1a"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnold H.","family":"Zea","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Parasitology, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas Alberto","family":"Diazgranados-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Neurology Outpatient, Neurological Care Center \u2018Neur\u00f3logos de Occidente\u2019, Cali, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"R1-20251107","doi-asserted-by":"crossref","first-page":"6488","DOI":"10.3390\/ijms25126488","article-title":"A systematic review of the predictive and diagnostic uses of neuroinflammation biomarkers for epileptogenesis.","volume":"25","author":"Aguilar-Castillo","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"Suppl 2","key":"R2-20251107","first-page":"2.266","article-title":"A phase 2a randomized double-blind dose-finding study to assess safety, tolerability and efficacy of adjunctive EQU-001 in adults with epilepsy.","volume":"23","year":"2023","journal-title":"Epilepsy Curr"},{"key":"R3-20251107","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0928-0987(98)00010-4","article-title":"Influence of propylene glycol and isopropyl myristate on the in vitro percutaneous penetration of diclofenac sodium from carbopol gels.","volume":"7","author":"Arellano","year":"1999","journal-title":"Eur J Pharm Sci"},{"key":"R4-20251107","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1093\/ije\/dyg286","article-title":"Fisher, Bradford Hill, and randomization.","volume":"32","author":"Armitage","year":"2003","journal-title":"Int J Epidemiol"},{"key":"R5-20251107","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/jat\/16.2.97","article-title":"Propylene glycol as a vehicle for percutaneous absorption of therapeutic agents.","volume":"16","author":"Bailey","year":"1992","journal-title":"J Anal Toxicol"},{"key":"R6-20251107","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMc1917344","article-title":"Serious ivermectin toxicity and human ABCB1 nonsense mutations.","volume":"383","author":"Baudou","year":"2020","journal-title":"N Engl J Med"},{"key":"R7-20251107","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0378-5173(94)00267-9","article-title":"Influence of propylene glycol as cosolvent on mechanisms of drug transport from hydrogels.","volume":"116","author":"Bendas","year":"1995","journal-title":"Int J Pharm"},{"key":"R8-20251107","doi-asserted-by":"crossref","first-page":"e0011178","DOI":"10.1371\/journal.pntd.0011178","article-title":"Impact of a bi-annual community-directed treatment with ivermectin programme on the incidence of epilepsy in an onchocerciasis-endemic area of Mahenge, Tanzania: a population-based prospective study.","volume":"17","author":"Bhwana","year":"2023","journal-title":"PLoS Negl Trop Dis"},{"key":"R9-20251107","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/epi.18230","article-title":"Community-based epilepsy care in an onchocerciasis-endemic area: a 3-year cohort study in Mahenge, Tanzania.","volume":"66","author":"Bhwana","year":"2025","journal-title":"Epilepsia"},{"key":"R10-20251107","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1021\/acschemneuro.2c00783","article-title":"Structural elucidation of ivermectin binding to \u03b17nAChR and the induced channel desensitization.","volume":"14","author":"Bondarenko","year":"2023","journal-title":"ACS Chem Neurosci"},{"key":"R11-20251107","doi-asserted-by":"crossref","first-page":"104787","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.","volume":"178","author":"Caly","year":"2020","journal-title":"Antiviral Res"},{"key":"R13-20251107","doi-asserted-by":"crossref","first-page":"853","DOI":"10.2174\/138920112800399095","article-title":"History of avermectin and ivermectin, with notes on the history of other macrocyclic lactone antiparasitic agents.","volume":"13","author":"Campbell","year":"2012","journal-title":"Curr Pharm Biotechnol"},{"key":"R14-20251107","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1528-1167.2010.02520.x","article-title":"Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy.","volume":"51","author":"Canevini","year":"2010","journal-title":"Epilepsia"},{"key":"R15-20251107","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00403-019-02017-5","article-title":"Effect of propylene glycol on the skin penetration of drugs.","volume":"312","author":"Carrer","year":"2020","journal-title":"Arch Dermatol Res"},{"key":"R16-20251107","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1113\/JP275236","article-title":"Ivermectin and its target molecules: shared and unique modulation mechanisms of ion channels and receptors by ivermectin.","volume":"596","author":"Chen","year":"2018","journal-title":"J Physiol"},{"key":"R17-20251107","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","article-title":"Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study.","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol"},{"key":"R18-20251107","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00011-023-01700-8","article-title":"Neuroinflammatory mediators in acquired epilepsy: an update.","volume":"72","author":"Chen","year":"2023","journal-title":"Inflamm Res"},{"key":"R19-20251107","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.pt.2017.11.009","article-title":"Onchocerciasis-associated epilepsy, an additional reason for strengthening onchocerciasis elimination programs.","volume":"34","author":"Colebunders","year":"2018","journal-title":"Trends Parasitol"},{"key":"R20-20251107","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1124\/mol.110.064295","article-title":"Nicotinic acetylcholine receptor transmembrane mutations convert ivermectin from a positive to a negative allosteric modulator.","volume":"78","author":"Collins","year":"2010","journal-title":"Mol Pharmacol"},{"key":"R21-20251107","doi-asserted-by":"crossref","first-page":"741244","DOI":"10.3389\/fneur.2022.741244","article-title":"Targeting inflammatory mediators in epilepsy: a systematic review of its molecular basis and clinical applications.","volume":"13","author":"Costagliola","year":"2022","journal-title":"Front Neurol"},{"key":"R22-20251107","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/0028-3908(86)90154-1","article-title":"Anticonvulsant effects of ivermectin in genetically-epileptic chickens.","volume":"25","author":"Crichlow","year":"1986","journal-title":"Neuropharmacology"},{"key":"R23-20251107","doi-asserted-by":"crossref","first-page":"303","DOI":"10.33588\/rn.6507.2016574","article-title":"Ivermectina como coadyuvante en la epilepsia refractaria [Ivermectin as an adjunct in the treatment of refractory epilepsy].","volume":"65","author":"Diazgranados-Sanchez","year":"2017","journal-title":"Rev Neurol"},{"key":"R24-20251107","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/pathogens10010021","article-title":"Effect of ivermectin treatment on the frequency of seizures in persons with epilepsy infected with Onchocerca volvulus.","volume":"10","author":"Dusabimana","year":"2020","journal-title":"Pathogens"},{"key":"R25-20251107","first-page":"168","article-title":"Influence of cosolvents on the absorptive clearance of ketotifen fumarate from rabbit intestine, in-situ.","volume":"2","author":"El-Gizawy","year":"2018","journal-title":"J Adv Pharm Res"},{"key":"R27-20251107","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.yebeh.2012.04.128","article-title":"Seizure diaries for clinical research and practice: limitations and future prospects.","volume":"24","author":"Fisher","year":"2012","journal-title":"Epilepsy Behav"},{"key":"R29-20251107","doi-asserted-by":"crossref","first-page":"E885","DOI":"10.1208\/aapsj070486","article-title":"Neuronal nicotinic acetylcholine receptor expression and function on nonneuronal cells.","volume":"7","author":"Gahring","year":"2006","journal-title":"AAPS J"},{"key":"R30-20251107","doi-asserted-by":"crossref","first-page":"112073","DOI":"10.1016\/j.intimp.2024.112073","article-title":"Ivermectin ameliorates acute myocarditis via the inhibition of importin-mediated nuclear translocation of NF-\u03baB\/p65.","volume":"133","author":"Gao","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"R31-20251107","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.tvjl.2007.07.011","article-title":"The pharmacokinetics and metabolism of ivermectin in domestic animal species.","volume":"179","author":"Gonz\u00e1lez Canga","year":"2009","journal-title":"Vet J"},{"key":"R32-20251107","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10654-016-0149-3","article-title":"Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations.","volume":"31","author":"Greenland","year":"2016","journal-title":"Eur J Epidemiol"},{"key":"R33-20251107","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1177\/009127002237994","article-title":"Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects.","volume":"42","author":"Guzzo","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"R34-20251107","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/jps.20829","article-title":"Effect of propylene glycol on ibuprofen absorption into human skin in vivo.","volume":"97","author":"Herkenne","year":"2008","journal-title":"J Pharm Sci"},{"key":"R35-20251107","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nature10139","article-title":"Principios de activaci\u00f3n y permeaci\u00f3n en un receptor Cy-loop selectivo de aniones.","volume":"474","author":"Hibbs","year":"2011","journal-title":"Nature"},{"key":"R36-20251107","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1080\/15563650.2022.2134788","article-title":"Characteristics of ivermectin toxicity in patients taking veterinary and human formulations for the prevention and treatment of COVID-19.","volume":"60","author":"Hoang","year":"2022","journal-title":"Clin Toxicol"},{"key":"R37-20251107","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.3390\/cells9092100","article-title":"Ivermectin as a broad-spectrum host-directed antiviral: the real deal?","volume":"9","author":"Jans","year":"2020","journal-title":"Cells"},{"key":"R38-20251107","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s13046-019-1251-7","article-title":"Ivermectin reverses the drug resistance in cancer cells through EGFR\/ERK\/Akt\/NF-\u03baB pathway.","volume":"38","author":"Jiang","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"R39-20251107","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4103\/ijmr.IJMR_710_15","article-title":"Adverse effects & drug load of antiepileptic drugs in patients with epilepsy: monotherapy versus polytherapy.","volume":"145","author":"Joshi","year":"2017","journal-title":"Indian J Med Res"},{"key":"R40-20251107","first-page":"e56025","article-title":"Ivermectin: a multifaceted drug with a potential beyond anti-parasitic therapy.","volume":"16","author":"Kaur","year":"2024","journal-title":"Cureus"},{"key":"R41-20251107","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.neuron.2012.09.024","article-title":"Neuromodulation by extracellular ATP and P2X receptors in the CNS.","volume":"76","author":"Khakh","year":"2012","journal-title":"Neuron"},{"key":"R42-20251107","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1124\/mol.53.2.283","article-title":"Ivermectin: a positive allosteric effector of the alpha7 neuronal nicotinic acetylcholine receptor.","volume":"53","author":"Krause","year":"1998","journal-title":"Mol Pharmacol"},{"key":"R43-20251107","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy.","volume":"342","author":"Kwan","year":"2000","journal-title":"N Engl J Med"},{"key":"R44-20251107","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.0013-9580.2005.31904.x","article-title":"Potential role of drug transporters in the pathogenesis of medically intractable epilepsy.","volume":"46","author":"Kwan","year":"2005","journal-title":"Epilepsia"},{"key":"R45-20251107","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies.","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"R46-20251107","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1006\/taap.1996.8086","article-title":"P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity.","volume":"143","author":"Lankas","year":"1997","journal-title":"Toxicol Appl Pharmacol"},{"key":"R48-20251107","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2147\/DDDT.S237393","article-title":"Progress in understanding the molecular mechanisms underlying the antitumour effects of ivermectin.","volume":"14","author":"Liu","year":"2020","journal-title":"Drug Des Dev Ther"},{"key":"R49-20251107","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1124\/pr.120.019539","article-title":"Drug resistance in epilepsy: clinical impact, potential mechanisms, and new innovative treatment options.","volume":"72","author":"L\u00f6scher","year":"2020","journal-title":"Pharmacol Rev"},{"key":"R50-20251107","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3389\/fnmol.2012.00060","article-title":"Molecular mechanisms of Cys-loop ion channel receptor modulation by ivermectin.","volume":"5","author":"Lynagh","year":"2012","journal-title":"Front Mol Neurosci"},{"key":"R51-20251107","doi-asserted-by":"crossref","first-page":"e11375","DOI":"10.1016\/j.heliyon.2022.e11375","article-title":"Anticonvulsant effects of ivermectin on pentylenetetrazole- and maximal electroshock-induced seizures in mice: the role of GABAergic system and K(ATP) channels.","volume":"8","author":"Manavi","year":"2022","journal-title":"Heliyon"},{"key":"R52-20251107","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/epi4.13107","article-title":"Ivermectin as a promising therapeutic option for onchocerciasis-associated epilepsy.","volume":"10","author":"Manavi","year":"2025","journal-title":"Epilepsia Open"},{"key":"R53-20251107","doi-asserted-by":"crossref","first-page":"e0007966","DOI":"10.1371\/journal.pntd.0007966","article-title":"Ivermectin as an adjuvant to anti-epileptic treatment in persons with onchocerciasis-associated epilepsy: a randomized proof-of-concept clinical trial.","volume":"14","author":"Mandro","year":"2020","journal-title":"PLoS NeglTrop Dis"},{"key":"R54-20251107","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0378-4274(91)90143-T","article-title":"Modulation of monomethylhydrazine-induced seizures by ivermectin.","volume":"57","author":"Mayer","year":"1991","journal-title":"Toxicol Lett"},{"key":"R55-20251107","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/00008571-200111000-00012","article-title":"Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene.","volume":"11","author":"Mealey","year":"2001","journal-title":"Pharmacogenetics"},{"key":"R56-20251107","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/jac\/dkz524","article-title":"Safety of high-dose ivermectin: a systematic review and meta-analysis.","volume":"75","author":"Navarro","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"R57-20251107","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s40263-023-01025-4","article-title":"New GABA-targeting therapies for the treatment of seizures and epilepsy: II. Treatments in clinical development.","volume":"37","author":"Perucca","year":"2023","journal-title":"CNS Drugs"},{"key":"R58-20251107","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0006-2952(96)00656-9","article-title":"Reversal of P-glycoprotein-associated multidrug resistance by ivermectin.","volume":"53","author":"Pouliot","year":"1997","journal-title":"Biochem Pharmacol"},{"key":"R60-20251107","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12974-018-1192-7","article-title":"The role of inflammation in the development of epilepsy.","volume":"15","author":"Rana","year":"2018","journal-title":"J Neuroinflammation"},{"key":"R61-20251107","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.3390\/ijms25084161","article-title":"Neuroinflammation and epilepsy: from pathophysiology to therapies based on repurposing drugs.","volume":"25","author":"Sanz","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R62-20251107","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology.","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"R63-20251107","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/0092-8674(94)90212-7","article-title":"Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs.","volume":"77","author":"Schinkel","year":"1994","journal-title":"Cell"},{"key":"R64-20251107","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1007\/s11011-023-01290-8","article-title":"Neuroprotective effects of ivermectin against transient cerebral ischemia-reperfusion in rats.","volume":"38","author":"Seyyedabadi","year":"2023","journal-title":"Metab Brain Dis"},{"key":"R65-20251107","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/bs.apha.2014.10.002","article-title":"Allosteric modulation of GABAA receptors via multiple drug-binding sites.","volume":"72","author":"Sieghart","year":"2015","journal-title":"Adv Pharmacol"},{"key":"R66-20251107","first-page":"77","article-title":"Solvent system effects on drug absorption.","volume":"24","author":"Stavchansky","year":"1979","journal-title":"Res Commun Chem Pathol Pharmacol"},{"key":"R70-20251107","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1528-1167.2011.03355.x","article-title":"Revising the \u2018Rule of Three\u2019 for inferring seizure freedom.","volume":"53","author":"Westover","year":"2012","journal-title":"Epilepsia"},{"key":"R71-20251107","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.addr.2003.10.025","article-title":"Penetration enhancers.","volume":"56","author":"Williams","year":"2004","journal-title":"Adv Drug Deliv Rev"},{"key":"R73-20251107","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s10753-023-01829-y","article-title":"Ivermectin protects against experimental autoimmune encephalomyelitis in mice by modulating the Th17\/Treg balance involved in the IL-2\/STAT5 pathway.","volume":"46","author":"Xie","year":"2023","journal-title":"Inflammation"},{"key":"R74-20251107","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00249-023-01693-6","article-title":"Real-time tilting and twisting motions of ligand-bound states of \u03b17 nicotinic acetylcholine receptor.","volume":"53","author":"Yang","year":"2024","journal-title":"Eur Biophys J"},{"key":"R75-20251107","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s00011-008-8007-8","article-title":"Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice.","volume":"57","author":"Zhang","year":"2008","journal-title":"Inflamm Res"},{"key":"R76-20251107","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3390\/antiox11050908","article-title":"Ivermectin-induced apoptotic cell death in human SH-SY5Y cells involves the activation of oxidative stress and mitochondrial pathway and Akt\/mTOR-pathway-mediated autophagy.","volume":"11","author":"Zhang","year":"2022","journal-title":"Antioxidants (Basel)"}],"container-title":["Behavioural Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FBP.0000000000000858","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T10:01:43Z","timestamp":1762509703000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FBP.0000000000000858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":67,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/fbp.0000000000000858","relation":{},"ISSN":["0955-8810","1473-5849"],"issn-type":[{"type":"print","value":"0955-8810"},{"type":"electronic","value":"1473-5849"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"2025-05-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}